High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer

Yihong Wang, Joseph A. Sparano, Susan A. Fineberg, Lesley Stead, Jaya Sunkara, Susan Band Horwitz, Hayley M. McDaid

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Expression of class III β-tubulin (βIII-tubulin) correlates with tumor progression and resistance to taxane-based therapies for several human malignancies including breast cancer. However its predictive value in a neoadjuvant setting in breast cancer remains unexplored. The objective of this explorative study was to determine whether βIII-tubulin expression in breast cancer correlated with pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy. Patients and Methods: We determined βIII-tubulin expression in 85 breast cancers, including 41 localized breast cancers treated with primary surgery and 44 treated with neoadjuvant chemotherapy before surgery. βIII-tubulin expression was evaluated by immunohistochemical methods and was correlated with pathologic characteristics and response to neoadjuvant chemotherapy using residual cancer burden (RCB) score. Results: High βIII-tubulin expression was significantly associated with poorly differentiated high-grade breast cancers (P =.003) but not with tumor size, estrogen receptor (ER) status, or human epidermal growth factor receptor 2 (HER2)/neu overexpression. In ER - tumors treated with neoadjuvant chemotherapy, high βIII-tubulin expression was associated with a significantly greater likelihood of achieving a good pathologic response to chemotherapy as reflected by lower RCB scores (P =.021). Conclusion: This study reveals differential βIII-tubulin expression in breast cancers of different histologic grades, hormone receptors, and HER2/neu status. It also suggests a potential role for βIII-tubulin as a predictive biomarker for response in neoadjuvant chemotherapy for ER- breast cancer, which has not been previously reported. These data provide a strong rationale for considering βIII-tubulin status and further validation of this marker in a large study.

Original languageEnglish (US)
Pages (from-to)103-108
Number of pages6
JournalClinical Breast Cancer
Volume13
Issue number2
DOIs
StatePublished - 2013

Fingerprint

Tubulin
Estrogen Receptors
Doxorubicin
Cyclophosphamide
Breast Neoplasms
Drug Therapy
Residual Neoplasm
Neoplasms
taxane
Biomarkers
Hormones

Keywords

  • Breast cancer
  • Chemotherapy
  • Class III β-tubulin
  • Neoadjuvant
  • Predictive biomarker

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{cf299d378d48468da89688d737aac661,
title = "High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer",
abstract = "Background: Expression of class III β-tubulin (βIII-tubulin) correlates with tumor progression and resistance to taxane-based therapies for several human malignancies including breast cancer. However its predictive value in a neoadjuvant setting in breast cancer remains unexplored. The objective of this explorative study was to determine whether βIII-tubulin expression in breast cancer correlated with pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy. Patients and Methods: We determined βIII-tubulin expression in 85 breast cancers, including 41 localized breast cancers treated with primary surgery and 44 treated with neoadjuvant chemotherapy before surgery. βIII-tubulin expression was evaluated by immunohistochemical methods and was correlated with pathologic characteristics and response to neoadjuvant chemotherapy using residual cancer burden (RCB) score. Results: High βIII-tubulin expression was significantly associated with poorly differentiated high-grade breast cancers (P =.003) but not with tumor size, estrogen receptor (ER) status, or human epidermal growth factor receptor 2 (HER2)/neu overexpression. In ER - tumors treated with neoadjuvant chemotherapy, high βIII-tubulin expression was associated with a significantly greater likelihood of achieving a good pathologic response to chemotherapy as reflected by lower RCB scores (P =.021). Conclusion: This study reveals differential βIII-tubulin expression in breast cancers of different histologic grades, hormone receptors, and HER2/neu status. It also suggests a potential role for βIII-tubulin as a predictive biomarker for response in neoadjuvant chemotherapy for ER- breast cancer, which has not been previously reported. These data provide a strong rationale for considering βIII-tubulin status and further validation of this marker in a large study.",
keywords = "Breast cancer, Chemotherapy, Class III β-tubulin, Neoadjuvant, Predictive biomarker",
author = "Yihong Wang and Sparano, {Joseph A.} and Fineberg, {Susan A.} and Lesley Stead and Jaya Sunkara and {Band Horwitz}, Susan and McDaid, {Hayley M.}",
year = "2013",
doi = "10.1016/j.clbc.2012.11.003",
language = "English (US)",
volume = "13",
pages = "103--108",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer

AU - Wang, Yihong

AU - Sparano, Joseph A.

AU - Fineberg, Susan A.

AU - Stead, Lesley

AU - Sunkara, Jaya

AU - Band Horwitz, Susan

AU - McDaid, Hayley M.

PY - 2013

Y1 - 2013

N2 - Background: Expression of class III β-tubulin (βIII-tubulin) correlates with tumor progression and resistance to taxane-based therapies for several human malignancies including breast cancer. However its predictive value in a neoadjuvant setting in breast cancer remains unexplored. The objective of this explorative study was to determine whether βIII-tubulin expression in breast cancer correlated with pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy. Patients and Methods: We determined βIII-tubulin expression in 85 breast cancers, including 41 localized breast cancers treated with primary surgery and 44 treated with neoadjuvant chemotherapy before surgery. βIII-tubulin expression was evaluated by immunohistochemical methods and was correlated with pathologic characteristics and response to neoadjuvant chemotherapy using residual cancer burden (RCB) score. Results: High βIII-tubulin expression was significantly associated with poorly differentiated high-grade breast cancers (P =.003) but not with tumor size, estrogen receptor (ER) status, or human epidermal growth factor receptor 2 (HER2)/neu overexpression. In ER - tumors treated with neoadjuvant chemotherapy, high βIII-tubulin expression was associated with a significantly greater likelihood of achieving a good pathologic response to chemotherapy as reflected by lower RCB scores (P =.021). Conclusion: This study reveals differential βIII-tubulin expression in breast cancers of different histologic grades, hormone receptors, and HER2/neu status. It also suggests a potential role for βIII-tubulin as a predictive biomarker for response in neoadjuvant chemotherapy for ER- breast cancer, which has not been previously reported. These data provide a strong rationale for considering βIII-tubulin status and further validation of this marker in a large study.

AB - Background: Expression of class III β-tubulin (βIII-tubulin) correlates with tumor progression and resistance to taxane-based therapies for several human malignancies including breast cancer. However its predictive value in a neoadjuvant setting in breast cancer remains unexplored. The objective of this explorative study was to determine whether βIII-tubulin expression in breast cancer correlated with pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy. Patients and Methods: We determined βIII-tubulin expression in 85 breast cancers, including 41 localized breast cancers treated with primary surgery and 44 treated with neoadjuvant chemotherapy before surgery. βIII-tubulin expression was evaluated by immunohistochemical methods and was correlated with pathologic characteristics and response to neoadjuvant chemotherapy using residual cancer burden (RCB) score. Results: High βIII-tubulin expression was significantly associated with poorly differentiated high-grade breast cancers (P =.003) but not with tumor size, estrogen receptor (ER) status, or human epidermal growth factor receptor 2 (HER2)/neu overexpression. In ER - tumors treated with neoadjuvant chemotherapy, high βIII-tubulin expression was associated with a significantly greater likelihood of achieving a good pathologic response to chemotherapy as reflected by lower RCB scores (P =.021). Conclusion: This study reveals differential βIII-tubulin expression in breast cancers of different histologic grades, hormone receptors, and HER2/neu status. It also suggests a potential role for βIII-tubulin as a predictive biomarker for response in neoadjuvant chemotherapy for ER- breast cancer, which has not been previously reported. These data provide a strong rationale for considering βIII-tubulin status and further validation of this marker in a large study.

KW - Breast cancer

KW - Chemotherapy

KW - Class III β-tubulin

KW - Neoadjuvant

KW - Predictive biomarker

UR - http://www.scopus.com/inward/record.url?scp=84875182273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875182273&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2012.11.003

DO - 10.1016/j.clbc.2012.11.003

M3 - Article

C2 - 23218766

AN - SCOPUS:84875182273

VL - 13

SP - 103

EP - 108

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 2

ER -